We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.33%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.6B
AUM Growth
-$143M
Cap. Flow
-$225M
Cap. Flow %
-13.99%
Top 10 Hldgs %
36.09%
Holding
105
New
9
Increased
32
Reduced
29
Closed
12

Top Buys

Rank Stock Value
1
CAI
Caris Life Sciences
CAI
+$21.4M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$19.6M
3
OMDA
Omada Health Inc
OMDA
+$15.9M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$12.1M
5
ACLX
Arcellx
ACLX
+$11.6M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$85.4M
2
NUVL
Nuvalent
NUVL
+$24.5M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$21.8M
4
UNH icon
UnitedHealth
UNH
+$19.1M
5
LEGN icon
Legend Biotech
LEGN
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
26
DELISTED
Blueprint Medicines
BPMC
$23.8M 1.48%
185,500
-822,069
-82% -$85.4M
GPCR icon
27
Structure Therapeutics
GPCR
$3.78B
$23.6M 1.47%
1,135,879
+2,900
+0.3% +$63.8K
THC icon
28
Tenet Healthcare
THC
$21.1B
$22.9M 1.43%
130,000
– –
CAI
29
Caris Life Sciences
CAI
$6.43B
$21.2M 1.32%
+793,651
New +$21.4M
KYMR icon
30
Kymera Therapeutics
KYMR
$8.94B
$19.7M 1.22%
450,374
-344,063
-43% -$11.8M
OMDA
31
Omada Health Inc
OMDA
$1.41B
$16.8M 1.05%
+919,951
New +$15.9M
CLDX icon
32
Celldex Therapeutics
CLDX
$3.28B
$16.5M 1.03%
812,653
– –
AZTA icon
33
Azenta
AZTA
$1.48B
$16.3M 1.02%
530,400
+55,400
+12% +$1.56M
ACHC icon
34
Acadia Healthcare
ACHC
$2.94B
$15.8M 0.98%
696,000
+14,900
+2% +$353K
UNH icon
35
UnitedHealth
UNH
$370B
$15.8M 0.98%
50,500
-50,000
-50% -$19.1M
TARS icon
36
Tarsus Pharmaceuticals
TARS
$2.84B
$15.1M 0.94%
373,750
+19,374
+5% +$872K
SMMT icon
37
Summit Therapeutics
SMMT
$11.1B
$15.1M 0.94%
710,000
-285,000
-29% -$6.5M
AGL icon
38
Agilon Health
AGL
$1.6B
$15.1M 0.94%
262,016
-15,984
-6% -$1.28M
OSCR icon
39
Oscar Health
OSCR
$8.61B
$15M 0.94%
700,000
-350,000
-33% -$5.2M
VERA icon
40
Vera Therapeutics
VERA
$2.36B
$14.5M 0.91%
617,396
+96,600
+19% +$2.17M
ELVN icon
41
Enliven Therapeutics
ELVN
$4.43B
$14.1M 0.88%
701,408
+235,537
+51% +$4.46M
INSP icon
42
Inspire Medical Systems
INSP
$1.74B
$14M 0.87%
107,500
+8,250
+8% +$1.2M
SLNO
43
DELISTED
Soleno Therapeutics
SLNO
$12.9M 0.81%
154,528
+30,433
+25% +$2.28M
CMPX icon
44
Compass Therapeutics
CMPX
$387M
$12.9M 0.8%
4,962,955
– –
XBI icon
45
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$12.6M 0.78%
+151,750
New +$12.1M
ACLX
46
DELISTED
Arcellx
ACLX
$12.3M 0.76%
+186,314
New +$11.6M
MREO
47
Mereo BioPharma
MREO
$47.3M
$12.1M 0.75%
4,465,292
-2,218,955
-33% -$5.36M
DHR icon
48
Danaher
DHR
$144B
$11.7M 0.73%
59,000
+200
+0.3% +$38.8K
FOLD
49
DELISTED
Amicus Therapeutics
FOLD
$11.2M 0.7%
1,960,334
+50,972
+3% +$329K
WST icon
50
West Pharmaceutical
WST
$24.9B
$11.2M 0.7%
51,030
-9,220
-15% -$1.97M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Rock Springs Capital Management held 105 positions worth $1.6B, down 8.2% from $1.75B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Rock Springs Capital Management withdrew a net $225M in Q2 2025, closing 12 positions and reducing 29 holdings. Its most notable exit was Legend Biotech, an estimated $17.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Rock Springs Capital Management opened a new position in Caris Life Sciences worth $21.2M.

  • Rock Springs Capital Management's largest Q2 2025 buy was Caris Life Sciences: 793,651 shares worth $21.2M.
  • Rock Springs Capital Management added most to Agios Pharmaceuticals in Q2 2025, an estimated $19.6M increase.
  • Rock Springs Capital Management's biggest Q2 2025 reduction was Blueprint Medicines, cutting an estimated $85.4M.
  • Rock Springs Capital Management fully exited Legend Biotech in Q2 2025, selling an estimated $17.4M.
  • Rock Springs Capital Management's ten largest holdings make up 36% of its $1.6B portfolio in Q2 2025.
  • Rock Springs Capital Management opened 9 new positions and closed 12 in Q2 2025.
  • Rock Springs Capital Management's portfolio value fell 8.2% quarter-over-quarter to $1.6B.

Based on Rock Springs Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.